198 related articles for article (PubMed ID: 38484871)
1. Efficacy of various dosing frequencies of dupilumab in patients with aspirin-exacerbated respiratory disease.
Brown AN; Laidlaw TM; Buchheit KM; Bensko JC; Corcoran RC; Bailey LB
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1647-1648. PubMed ID: 38484871
[No Abstract] [Full Text] [Related]
2. Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease.
Mustafa SS; Vadamalai K
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):738-739. PubMed ID: 33746062
[No Abstract] [Full Text] [Related]
3. Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization.
Buchheit KM; Hacker J; Maurer R; McGill A; Ryan T; Bensko JC; Laidlaw TM
Clin Exp Allergy; 2023 Sep; 53(9):974-977. PubMed ID: 37246613
[No Abstract] [Full Text] [Related]
4. Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease.
Eid RC; Wudneh E; Zahid S; Cahill K; Jerschow E
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):102-104. PubMed ID: 31605753
[No Abstract] [Full Text] [Related]
5. Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.
Miss Ozuna L; Ryan T; Bensko JC; Laidlaw TM; Buchheit KM
Ann Allergy Asthma Immunol; 2022 Apr; 128(4):469-472. PubMed ID: 35124224
[No Abstract] [Full Text] [Related]
6. Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.
Patel P; Bensko JC; Bhattacharyya N; Laidlaw TM; Buchheit KM
Ann Allergy Asthma Immunol; 2022 Mar; 128(3):326-328. PubMed ID: 34863953
[No Abstract] [Full Text] [Related]
7. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.
Guillén D; Bobolea I; Calderon O; Fiandor A; Cabañas R ; Heredia R; Quirce S
J Investig Allergol Clin Immunol; 2015; 25(2):133-5. PubMed ID: 25997307
[No Abstract] [Full Text] [Related]
8. Mepolizumab for the treatment of aspirin-exacerbated respiratory disease associated with coronary spasm.
Hagin D; Shacham Y; Kivity S; Benor S
J Allergy Clin Immunol Pract; 2019 Mar; 7(3):1076-1077. PubMed ID: 30172017
[No Abstract] [Full Text] [Related]
9. Dupilumab improves alcohol tolerance in aspirin-exacerbated respiratory disease.
Arnold M; Kuruvilla M; Levy JM; Xu J
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):379-381. PubMed ID: 34004275
[No Abstract] [Full Text] [Related]
10. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease.
Aksu K; Kurt E
Allergol Immunopathol (Madr); 2013; 41(3):208-10. PubMed ID: 22763305
[No Abstract] [Full Text] [Related]
11. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease.
Tuttle KL; Buchheit KM; Laidlaw TM; Cahill KN
J Allergy Clin Immunol Pract; 2018; 6(3):1045-1047. PubMed ID: 29501519
[No Abstract] [Full Text] [Related]
12. Pediatric-onset aspirin-exacerbated respiratory disease: Clinical characteristics, prevalence, and response to dupilumab.
Bensko JC; McGill A; Palumbo M; Cahill KN; Laidlaw TM
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2466-2468. PubMed ID: 35643277
[No Abstract] [Full Text] [Related]
13. Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: A case series.
Martin H; Barrett NA; Laidlaw T
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1384-1385. PubMed ID: 32956852
[No Abstract] [Full Text] [Related]
14. Aspirin-Exacerbated Respiratory Disease in a Pediatric Patient Treated with Mepolizumab.
Méndez Sánchez A; Gutiérrez Martínez JR; Coca Pelaz A; Vázquez Piñera MA
Arch Bronconeumol (Engl Ed); 2019 Jan; 55(1):55-57. PubMed ID: 29853258
[No Abstract] [Full Text] [Related]
15. Factors correlated with repeated aspirin dosing during aspirin desensitization.
Schuler CF; Baldwin JL; Baptist AP
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):111-116.e1. PubMed ID: 29653235
[TBL] [Abstract][Full Text] [Related]
16. Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease.
Comert S; Celebioglu E; Yucel T; Erdogan T; Karakaya G; Onerci M; Kalyoncu AF
Allergy; 2013 Nov; 68(11):1443-51. PubMed ID: 24117703
[TBL] [Abstract][Full Text] [Related]
17. Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease.
Lee-Sarwar K; Johns C; Laidlaw TM; Cahill KN
J Allergy Clin Immunol Pract; 2015; 3(3):449-51. PubMed ID: 25634222
[No Abstract] [Full Text] [Related]
18. Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial.
Cahill KN; Cui J; Kothari P; Murphy K; Raby BA; Singer J; Israel E; Boyce JA; Laidlaw TM
Am J Respir Crit Care Med; 2019 Sep; 200(6):704-711. PubMed ID: 30978291
[No Abstract] [Full Text] [Related]
19. Decreased nasal polyp eosinophils but increased mast cells in a patient with aspirin-exacerbated respiratory disease treated with reslizumab.
Staudacher AG; Peters AT; Carter RG; Welch KC; Stevens WW
Ann Allergy Asthma Immunol; 2020 Oct; 125(4):490-493.e2. PubMed ID: 32629015
[No Abstract] [Full Text] [Related]
20. Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.
Hayashi H; Fukutomi Y; Mitsui C; Kajiwara K; Watai K; Kamide Y; Nakamura Y; Hamada Y; Tomita Y; Sekiya K; Tsuburai T; Izuhara K; Wakahara K; Hashimoto N; Hasegawa Y; Taniguchi M
Am J Respir Crit Care Med; 2020 Jun; 201(12):1488-1498. PubMed ID: 32142372
[No Abstract] [Full Text] [Related]
[Next] [New Search]
